Estados Unidos · Agencias y tiempo real · PR Newswire

Harbour BioMed Receives China NMPA Approval of Batoclimab Injection (Subcutaneous Injection) for the Treatment of Generalized Myasthenia Gravis

Publicado por PR Newswire · Estados Unidos hace 1 h

The first NMPA-approved anti-FcRn therapy to complete its full clinical development for gMG patients in China CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 22, 2026…

Leer el artículo completo en PR Newswire Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.prnewswire.com)

Harbour BioMed Receives China NMPA Approval of Batoclimab Injection (Subcutaneous Injection) for the Treatment of Generalized Myasthenia Gravis

También te puede interesar

The Ford Foundation, one of the world’s largest grantmakers, will throw more weight behind democracy

You.com Launches Inference Router, Bringing Enterprise-Grade Reliability to Open-Weight AI Models On Demand

Advancing Government Intelligence: Insights From the Data and Intelligence Training Forum

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows

Harbour BioMed Receives China NMPA Approval of Batoclimab Injection (Subcutaneous Injection) for the Treatment of Generalized Myasthenia Gravis

Compartir

También te puede interesar

The Ford Foundation, one of the world’s largest grantmakers, will throw more weight behind democracy

You.com Launches Inference Router, Bringing Enterprise-Grade Reliability to Open-Weight AI Models On Demand

Advancing Government Intelligence: Insights From the Data and Intelligence Training Forum

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows